WASHINGTON (dpa-AFX) – Neurocrine Biosciences Inc. (NBIX) on Monday reported positive two-year data from its Phase 3 CAHtalyst Pediatric study of Crenessity in children and adolescents with classi…
Neurocrine Reports Positive Two-Year Phase 3 Data For Crenessity In Pediatric CAH
Source: Finanznachrichten.de
Read Full Story →
